Aviva PLC lifted its position in shares of DaVita Inc. (NYSE:DVA - Free Report) by 427.7% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 27,921 shares of the company's stock after buying an additional 22,630 shares during the period. Aviva PLC's holdings in DaVita were worth $4,176,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors have also recently made changes to their positions in the company. MML Investors Services LLC lifted its holdings in shares of DaVita by 1.3% in the 3rd quarter. MML Investors Services LLC now owns 5,300 shares of the company's stock worth $869,000 after acquiring an additional 68 shares during the last quarter. Exchange Traded Concepts LLC grew its stake in shares of DaVita by 8.3% during the fourth quarter. Exchange Traded Concepts LLC now owns 891 shares of the company's stock worth $133,000 after purchasing an additional 68 shares in the last quarter. Impact Partnership Wealth LLC lifted its stake in DaVita by 3.7% during the fourth quarter. Impact Partnership Wealth LLC now owns 1,941 shares of the company's stock worth $290,000 after purchasing an additional 70 shares during the last quarter. Contravisory Investment Management Inc. lifted its position in DaVita by 1.2% in the fourth quarter. Contravisory Investment Management Inc. now owns 6,082 shares of the company's stock valued at $910,000 after acquiring an additional 73 shares during the last quarter. Finally, Nilsine Partners LLC raised its position in DaVita by 0.8% in the 4th quarter. Nilsine Partners LLC now owns 11,160 shares of the company's stock valued at $1,669,000 after purchasing an additional 92 shares during the last quarter. Hedge funds and other institutional investors own 90.12% of the company's stock.
DaVita Stock Down 2.3 %
NYSE DVA traded down $3.51 during trading hours on Tuesday, reaching $147.37. 198,150 shares of the company traded hands, compared to its average volume of 823,013. The company has a 50 day moving average of $151.61 and a two-hundred day moving average of $156.51. The stock has a market capitalization of $11.79 billion, a PE ratio of 13.71, a PEG ratio of 1.07 and a beta of 1.04. DaVita Inc. has a 12 month low of $125.64 and a 12 month high of $179.60. The company has a current ratio of 1.26, a quick ratio of 1.21 and a debt-to-equity ratio of 23.18.
DaVita (NYSE:DVA - Get Free Report) last announced its quarterly earnings data on Thursday, February 13th. The company reported $2.24 earnings per share for the quarter, beating the consensus estimate of $2.14 by $0.10. DaVita had a return on equity of 115.48% and a net margin of 7.31%. As a group, equities analysts expect that DaVita Inc. will post 10.76 earnings per share for the current year.
Analysts Set New Price Targets
A number of equities research analysts recently commented on DVA shares. Cowen restated a "hold" rating on shares of DaVita in a research report on Tuesday, February 18th. Sanford C. Bernstein set a $184.00 target price on shares of DaVita in a research note on Friday, February 21st. Barclays increased their price target on shares of DaVita from $164.00 to $169.00 and gave the stock an "equal weight" rating in a research note on Tuesday, February 18th. Finally, StockNews.com raised shares of DaVita from a "hold" rating to a "buy" rating in a research report on Thursday, April 10th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $166.33.
Get Our Latest Analysis on DaVita
DaVita Profile
(
Free Report)
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Recommended Stories
Before you consider DaVita, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DaVita wasn't on the list.
While DaVita currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
